国: オーストラリア
言語: 英語
ソース: Department of Health (Therapeutic Goods Administration)
nicotine polacrilex, Quantity: 26.66 mg (Equivalent: nicotine, Qty 4 mg)
Orion Laboratories Pty Ltd T/A Perrigo Australia
Nicotine polacrilex
Tablet, uncoated
Excipient Ingredients: mannitol; sodium carbonate; aspartame; potassium bicarbonate; sodium alginate; xanthan gum; magnesium stearate; Flavour
Buccal
168, 36, 288, 216, 120, 132, 144, 72, 96, 108, 156
Not Scheduled after consideration by Committee
Relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. Nicotine Lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. If possible, when stopping smoking, should be used in conjunction with behavioural support program.
Visual Identification: Cream/white embossed biconvex round tablet with a peppermint odour. Embossed with ?L873? on one face; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius
Licence status A
2016-06-23